Sulfur 8 Scalp Therapy Medicated Dandruff Control Leave-In Soothing Treatment

Manufacturer
J. Strickland and Co.
Effective date
2023-10-21
Label type
HUMAN OTC DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 23:57:07

Label at a glance#

ProductSulfur 8 Scalp Therapy Medicated Dandruff Control Leave-In Soothing Treatment
Active ingredientSALICYLIC ACID
Label structure6 sections

Dosage and administration

Apply to the affected area one to four times daily or as directed by a doctor. Use after shampooing or between shampoos.

Label contents#

Full prescribing information#

Active Ingredient

OTC - ACTIVE INGREDIENT SECTION

Salicylic Acid, 2%

Purpose

OTC - PURPOSE SECTION

Antidandruff, Seborrheic Dermatitis, Psoriasis

Use:

INDICATIONS & USAGE SECTION

for relief of scalp itching, irritation, redness, scaling and flaking associated with dandruff, seborrheic dermatitis, psoriasis.

Warnings

WARNINGS SECTION

For external use only

Ask a doctor before use

OTC - ASK DOCTOR SECTION

if the condition covers a large area of the body.

When using this product

OTC - WHEN USING SECTION

avoid contact with eyes. If contact, rinse eyes thoroughly with water.

Stop use and consult a doctor if

OTC - STOP USE SECTION

condition worsens or does not improve after regular use of this product as directed.

Keep out of reach of children.

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

If swallowed, get medical help or contact a Poison Control Center right away.

Keep away from heat and open flame. Flammable

Directions

DOSAGE & ADMINISTRATION SECTION

Apply to the affected area one to four times daily or as directed by a doctor. Use after shampooing or between shampoos.

Inactive Ingredients

INACTIVE INGREDIENT SECTION

Water, SD Alcohol 40, Propylene Glycol, Benzyl Alcohol, Menthol, Fragrance

Package Labeling:

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Outer PackageOuter PackageInner PackageInner Package

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
251294salicylic acid 3 % Topical SolutionPSN3
251294salicylic acid 30 MG/ML Topical SolutionSCD3
251294salicylic acid 3 % Topical SolutionSY3

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
12022-033-00Sulfur 8 Scalp Therapy Medicated Dandruff Control Leave-In Soothing Treatment74 mL in 1 BOTTLESOLUTION743
12022-033-00Sulfur 8 Scalp Therapy Medicated Dandruff Control Leave-In Soothing Treatment1 in 1 BOXSOLUTION13

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
12022-033SULFUR 8 SCALP THERAPY MEDICATED DANDRUFF CONTROL LEAVE-IN SOOTHING TREATMENT (SALICYLIC ACID) SOLUTION [J. STRICKLAND AND CO.]3Current NDC, Legacy NDC, 2 package rows20231021_96b24a6f-3d6e-6d60-e053-2a95a90a8330.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
12022-03312022-033-00

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Sulfur 8 Scalp Therapy Medicated Dandruff Control Leave-In Soothing TreatmentSALICYLIC ACIDJ. Strickland and Co.96b24a6f-3d6e-6d60-e053-2a95a90a83302023-10-21WarningsExact identifier
ndc (package): 12022-033-00
ndc (product): 12022-033
ndc11 (package): 12022003300
spl id: 0834f4b7-cad7-182f-e063-6294a90a7faa
spl set id: 96b24a6f-3d6e-6d60-e053-2a95a90a8330

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.